CClinicalTrials.gg
CompletedNCT04635501Updated Sep 5, 2021

AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial

An interventional study of ABS 5.6.7 in Peripheral Arterial Disease, sponsored by ID3 Medical. Completed at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by ID3 Medical · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates the efficacy and safety of the AbsorbaSeal (ABS 5.6.7.) Vascular Closure device (VCD) for the closure of access site of patients requiring percutaneous diagnostic or interventional procedures. An expected total of 50 patients will be enrolled in this study. A total of 12 patients (4 patients per site) will be treated as roll-in phase, prior to enrollment of the first patient. The primary objective of this study is to assess the safety and effectiveness of the ABS 5.6.7. VCD in sealing the femoral arterial access site following diagnostic or interventional peripheral or coronary procedures. Following physician training, patients will be enrolled. Efficacy and safety analyses will be based on these patients. Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures and health-related quality of life.

Read the detailed description

With the increased number of percutaneous interventions being performed in outpatient settings, there is a growing need to obtain safer, faster, and more secure hemostasis following these procedures. Due to its automatic deployment feature and simplicity in operation. AbsorbaSeal (ABS 5.6.7) will lead to more widespread use and improve patient outcomes. The active closure system used in the ABS 5.6.7 ensures a secure closure. The composition of the seal used is completely bio-absorbable and does not require the use of adjunct materials (i.e. collagen, sutures, staples, etc.) needed in many of the devices currently available.

Extensive laboratory testing, acute animal labs and deployment in chronic animal studies were performed with ABS 6. After a few device modification to create the improved ABS 5.6.7, only minimal confirmatory testing was performed with the current, modified ABS 5.6.7. The extensive test results on the previous device iterations are used to complete the confirmatory testing of the ABS 5.6.7 design.

The First in Man (FIM) trial (CP001) supports the initial safety and effectiveness of ABS 5.6.7 in humans (n=20) and was completed prior to application for a pivotal Investigational Device Exemption (IDE) Study in the United States and a CE Mark Study approval (CP004CE) in the European Union.

The primary objective of this study is to assess the safety and effectiveness of the ABS 5.6.7. Enrollment into this study will include anatomically eligible patients requiring diagnostic and interventional procedures. Patients will be followed procedurally to discharge, at one month, (follow-up commitment). Secondary objectives are to further characterize adverse events (serious and non-serious), clinical utility measures, and health-related quality of life.

02

Conditions studied

03

In context

Peripheral Arterial Disease

1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.

This study's enrollment of 61 is below the median of 74 across 1,066 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

ID3 Medical is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient, male or female, minimum age of 18
  • Patient provides written Informed Consent
  • Patient is scheduled for a peripheral diagnostic or interventional procedure
  • Patient is able to undergo emergent vascular surgery if a complication related to the VCD necessitates such surgery
  • Patient has a 6French arterial puncture located in the common femoral artery (CFA)
  • Target vessel has a lumen diameter > 5 mm
  • Patient is willing and able to comply with all Study visits and procedures and complete follow-up visit
  • Catheterization procedure is planned and elective

Pre-Procedure Exclusion Criteria:

  • Prior target artery closure with any closure device or closure with manual compression ≤ 30 days prior to the peripheral catheterization procedure
  • History of significant bleeding or with any known or documented bleeding disorders, such as thrombocytopenia (with \< 100,000 platelet count), von Willebrand disease, anemia (Hgb \< 10 g/Dl, Hct \< 30%), thrombasthenia, decreased fibrinogen (\< 200 mg/Dl), and Factor V deficiency
  • Acute ST-elevation myocardial infarction ≤ 48 hours prior to the peripheral catheterization procedure
  • Ineligible for introducer sheath removal
  • Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) ≤ 24 hours prior to the peripheral catheterization procedure
  • Evidence of a preexisting hematoma, arteriovenous fistula, or pseudo-aneurysm at the access site prior to start of femoral artery closure procedure
  • Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery
  • Targeted femoral artery is tortuous or requires a sheath length > 10 cm
  • Pregnant or lactating
  • Mean body mass index (BMI) > 35 kg/m²
  • Existing nerve damage in ipsilateral limb
  • Fibrotic, heavily calcified femoral artery within 10mm of the entry point
  • Non-palpable pulses in affected access limb

Intra-Procedure Exclusion Criteria:

  • Difficult insertion of procedural sheath, needle stick problems at the onset of the peripheral procedure or difficult insertion of ABS 5.6.7
  • Procedural sheath placement either through superficial femoral artery or into the profunda femoris artery or placement at or distal to bifurcation of the superficial femoral artery and the profunda femoris artery
  • Common femoral artery (CFA) puncture site located above the lowest sweep of the inferior epigastric artery; referred to as a "high stick"
  • Common femoral artery (CFA) access puncture site located on the front wall that continues through the back wall of the targeted vessel; referred to as a "back wall stick"
  • Common femoral artery (CFA) access puncture site with multiple punctures of the CFA in an attempt to gain access to the targeted vessel known as "multiple sticks"
  • Common femoral artery (CFA) access puncture located in the side wall region of the targeted access vessel; referred to as a "side wall stick"
  • Interventional procedures with multiple exchanges during the procedure that cause elongation and trauma to the vessel compromising the tight seal between the vessel and the sheath
  • Hematoma developing during the course of the percutaneous procedure
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    ABS 5.6.7

    Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device

    Device: ABS 5.6.7

Interventions

  • DeviceABS 5.6.7

    Patients whose access site will be closed with the ABS 5.6.7

06

What researchers measure

Primary outcomes

  1. Rate of major complications

    Composite of (1) closure-related bleeding requiring transfusion, (2) closure related vascular injury requiring repair surgery, (3) new ipsilateral lower extremity ischemia causing a threat to viability of limb requiring surgical or endovascular intervention, (4) closure-related infection requiring intravenous antibiotics and/or extended hospitalization, (5) new onset closure-related neuropathy in the ipsilateral lower extremity requiring surgical repair, and (6) permanent closure-related nerve damage.

    Time frame: Post-procedure follow up 30 ± 7 days

  2. Time to hemostasis (TTH) after index procedure (min)

    TTH is defined as elapsed time between ABS 5.6.7 removal and first observed hemostasis

    Time frame: Intraoperative

Secondary outcomes

  1. Rate of minor complications

    Composite of (1) closure-related bleeding requiring \> 30 min. of continual manual compression to achieve initial arterial hemostasis, (2) late closure-related arterial bleeding (following hospital discharge), (3) closure-related hematoma \> 6 cm, (4) Ipsilateral lower extremity arterial emboli, (5) ipsilateral deep vein thrombosis, (6) closure-related vessel laceration, (7) access site wound dehiscence, (8) localized access site infection treated with intramuscular or oral antibiotics, (9) closure related arteriovenous fistula not requiring treatment, (10) closure related pseudo-aneurysm requiring thrombin injection or fibrin adhesive injection, (11) closure related pseudo-aneurysm not requiring treatment, and (12) new onset of transient access site closure related neuropathy in the ipsilateral lower extremity that is transient (\> 24 hrs. and \< 30 days) and does not require surgical repair

    Time frame: Post-procedure follow up 30 ± 7 days

  2. Device success

    Device Success defined as the ability to deploy the implant and achieve arterial hemostasis with ABS 5.6.7 alone or with post hemostasis adjunctive manual compression for 5 minutes or less.

    Time frame: Within 5 minutes following ABS 5.6.7 deployment

  3. Procedure success

    Procedure Success defined as attainment of final arterial hemostasis using any method.

    Time frame: Post-procedure follow up 30 ± 7 days

07

Study locations

2 sites
  • O.L.V. Hospital
    Aalst, 9300, Belgium
  • A.Z. Sint-Blasius
    Dendermonde, 9200, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04635501
Lead sponsor
ID3 Medical
Collaborators
CyndRx, LLC
Responsible party
Sponsor
First posted
Nov 19, 2020
Start date
Sep 23, 2020
Primary completion
May 5, 2021
Completion
Jun 7, 2021
Last update
Sep 5, 2021

Study contacts

Koen Deloose, MD
principal investigator · AZ Sint Blasius

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion